Prothrombin complex concentrates in emergency bleeding disorders

Am J Hematol. 2012 Sep;87(9):898-902. doi: 10.1002/ajh.23254. Epub 2012 May 31.


The use of prothrombin complex concentrates (PCCs), a heterogeneous combination of coagulation factors and counterbalancing inhibitor components, has broadened in recent years beyond single-factor replacement in conditions such as hemophilia B, to encompass emergency reversal of anticoagulation secondary to oral vitamin K antagonists, ie, warfarin therapy. PCCs also have been studied in other bleeding disorders, such as surgery-related and trauma-related bleeding. This review provides an updated examination of the differences among PCC formulations, their potential role in the management of bleeding disorders, and the primary safety issues affecting their use. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Coagulation / drug effects*
  • Blood Coagulation Factors / administration & dosage
  • Blood Coagulation Factors / adverse effects
  • Blood Coagulation Factors / therapeutic use*
  • Emergency Medical Services / methods*
  • Hemorrhage / blood
  • Hemorrhage / drug therapy*
  • Hemorrhage / etiology
  • Humans
  • International Normalized Ratio


  • Blood Coagulation Factors
  • prothrombin complex concentrates